Global Plasma Fractionation Market Forecast to 2028 –

Dublin, Jan. 28, 2022 (GLOBE NEWSWIRE) — The “Plasma Fractionation Market Forecast to 2028 – Impact of COVID-19 and Global Analysis” report has been added to from ResearchAndMarkets.com offer.

Plasma fractionation market is expected to reach US$40,731.98 million by 2028 from US$26,575.83 million in 2021; it is expected to grow at a CAGR of 6.3% over the period 2021-2028.

The growth of the market is mainly attributed to the growing application of plasma therapy and the active participation of companies in market developments. However, the availability of recombinant or non-plasma homologs. Moreover, the potential for development in emerging countries offers lucrative opportunities for the growth of the plasma fractionation market.

As indicated in the previous pilot, the market offers considerable potential for companies exploiting market-related activities. Due to the positive market growth, global and regional market players are actively adopting organic and inorganic development strategies. Thus, it is expected to attract larger investments in the market over the forecast period. For example, here are some of the developments and initiatives adopted by market players.

Based on application, the plasma fractionation market is segmented into neurology, immunology, hematology, critical care, pulmonology, and other applications. The neurology segment is expected to hold the largest market share in 2021 and is expected to register the highest CAGR during the forecast period. The plasma fractionation market, by product, is segmented into immunoglobulin, albumin, coagulation factor concentrates, protease inhibitors and other plasma products. The immunoglobulin segment is estimated to hold the largest market share in 2021, and it is further expected to register the highest CAGR in the market during the period 2021-2028.

Food Safety and Inspection Service, Food and Drug Administration, and European Medical Association are some of the major secondary sources mentioned while preparing the global Plasma Fractionation market report.

Reasons to buy

  • Save and reduce time spent on entry-level research by identifying the growth, size, leading players and segments in the Plasma Fractionation market.
  • Highlights key business priorities to help companies realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the Global Plasma Fractionation Market, thereby allowing players across the value chain to develop effective long term strategies.
  • Develop/modify business expansion plans using substantial growth offering in both developed and emerging markets.
  • Dig deep into the global market trends and outlook associated with the factors driving the market, as well as those hindering it.
  • Improve the decision-making process by understanding the strategies that underpin security interest with respect to customer products, segmentation, pricing and distribution

Main topics covered:

1. Introduction

2. Global Plasma Fractionation Market – Key Takeaways

3. Research methodology

4. Plasma Fractionation Market – Market Landscape
4.1 Overview
4.2 PEST analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe – PEST analysis
4.2.3 Asia Pacific – PEST Analysis
4.2.4 Middle East and Africa – PEST Analysis
4.2.5 South & Central America (SCAM) – PEST Analysis
4.3 Expert advice

5. Plasma Fractionation Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Application of Plasma Therapy
5.1.2 Active participation of players in market developments
5.2 Market Constraints
5.2.1 Availability of non-plasma substitutes
5.3 Market Opportunities
5.3.1 Development potential in emerging countries
5.4 Future trends
5.4.1 Use of plasma therapy for the treatment of new diseases
5.5 Impact analysis

6. Plasma Fractionation Market – Global Analysis
6.1 Global Plasma Fractionation Market Revenue Forecast and Analysis
6.2 Global Plasma Fractionation Market, by Geography – Forecast and Analysis
6.3 Market Positioning of Key Players

7. Plasma Fractionation Market Revenue and Forecast to 2028 – By Product
7.1 Overview
7.2 Global Plasma Fractionation Market, By Product 2021 & 2028 (%)
7.3 Immunoglobulin
7.3.1 Overview
7.3.2 Immunoglobulin: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
7.3.2.1 Intravenous immunoglobulin (IVIg)
7.3.2.1.1 Presentation
7.3.2.1.2 Intravenous Immunoglobulin: Plasma Fractionation Market Revenue and Forecast to 2028 (USD Million)
7.3.2.2 Subcutaneous immunoglobulin (SCIG)
7.3.2.2.1 Presentation
7.3.2.2.2 Subcutaneous Immunoglobulin: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
7.4 Albumin
7.4.1 Overview
7.4.2 Albumin: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
7.5 Clotting factor concentrates
7.5.1 Overview
7.5.2 Coagulation Factor Concentrates: Plasma Fractionation Market Revenue and Forecast to 2028 (USD Million)
7.6 Protease inhibitors
7.6.1 Overview
7.6.2 Protease Inhibitors: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
7.7 Other plasma products
7.7.1 Preview
7.7.2 Other Plasma Products: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)

8. Plasma Fractionation Market Revenue and Forecast to 2028 – Application
8.1 Overview
8.2 Global Plasma Fractionation Market Share by Application 2021 & 2028 (%)
8.3 Neurology
8.3.1 Overview
8.3.2 Neurology: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
8.4 Immunology
8.4.1 Preview
8.4.2 Immunology: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
8.5 Hematology
8.5.1 Overview
8.5.2 Hematology: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
8.6 Intensive care
8.6.1 Preview
8.6.2 Critical Care: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
8.7 Pneumology
8.7.1 Preview
8.7.2 Pneumology: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
8.8 Other applications
8.8.1 Preview
8.8.2 Other Applications: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)

9. Plasma Fractionation Market Revenue and Forecast to 2028 – End User
9.1 Overview
9.2 Global Plasma Fractionation Market Share by End User 2021 & 2028 (%)
9.3 Hospitals and clinics
9.3.1 Preview
9.3.2 Hospitals & Clinics: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
9.4 Clinical research laboratories
9.4.1 Preview
9.4.2 Clinical Research Laboratories: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)
9.5 University institutes
9.5.1 Preview
9.5.2 Academic Institutes: Plasma Fractionation Market Revenue and Forecast to 2028 (Million USD)

10. Plasma Fractionation Market Revenue and Forecast to 2028 – Geographical Analysis

11. Impact of the COVID-19 pandemic on the plasma fractionation market
11.1 North America: Assessing the Impact of the COVID-19 Pandemic
11.2 Europe: assessment of the impact of the COVID-19 pandemic
11.3 Asia-Pacific: Assessing the impact of the COVID-19 pandemic
11.4 South and Central America: Assessing the impact of the COVID-19 pandemic
11.5 Middle East and Africa: Assessing the impact of the COVID-19 pandemic
11.6 South and Central America: Assessing the impact of the COVID-19 pandemic

12. Plasma Fractionation Market-Industry Landscape
12.1 Overview
12.2 Growth Strategies Followed by Key Market Players (%)
12.3 Organic developments
12.3.1 Presentation
12.4 Inorganic developments
12.4.1 Presentation

13. Business Profiles
13.1 Biotest SA.
13.1.1 Key Facts
13.1.2 Description of the activity
13.1.3 Products and services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Octapharma S.A.
13.2.1 Key Facts
13.2.2 Description of the activity
13.2.3 Products and services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Main developments
13.3 Kedrion SpA
13.3.1 Key Facts
13.3.2 Description of the activity
13.3.3 Products and services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Main developments
13.4 CSL Limited
13.4.1 Key Facts
13.4.2 Description of activity
13.4.3 Products and services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Grifols, SA
13.5.1 Key Facts
13.5.2 Description of activity
13.5.3 Products and services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Organic Products Laboratory Ltd.
13.6.1 Key Facts
13.6.2 Description of activity
13.6.3 Products and services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Sanquin
13.7.1 Key Facts
13.7.2 Description of activity
13.7.3 Products and services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Sera and Vaccines Bharat Limited (BSV)
13.8.1 Key Facts
13.8.2 Description of activity
13.8.3 Products and services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 SK Plasma
13.9.1 Key Facts
13.9.2 Description of activity
13.9.3 Products and services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Major Developments
13.10 PlasmaGen BioSciences Pvt. ltd.
13.10.1 Key Facts
13.10.2 Description of activity
13.10.3 Products and services
13.10.4 Financial overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

For more information on this report, visit https://www.researchandmarkets.com/r/k5aogy


About Clara Barnard

Check Also

Global Hemophilia Treatment Market Report to 2031: Players

Dublin, Nov. 11, 2022 (GLOBE NEWSWIRE) — The “Hemophilia Treatment Market by Type, by Drug …